Advertisement

The Coagulation System and Angiogenesis

  • Gurinder Sidhu
  • Gerald A. Soff
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 148)

In 1865, Armand Trousseau recognized the relationship between an activated coagulation system and malignancy [1]. He suggested that patients presenting with idiopathic venous thrombosis might be harboring an occult cancer. Numerous recent studies have also demonstrated an increased odds ratio of patients with idiopathic venous thromboembolic disease having an occult malignancy (i.e. [2]). Venous thromboembolic disease (VTE) is the second most common cause of death in cancer patients, after deaths from the underlying malignancy [3]. The prevalence of VTE depends on tumor type and treatment received. Recent studies note that activation of the coagulation system, in addition to predisposing to VTE, may also contribute directly to the growth of primary and metastatic cancers, in large part by promoting angiogenesis. In this chapter, we will review the role of platelets and the coagulation system in promoting tumor-associated angiogenesis. We will also discuss the effects of anticoagulation on angiogenesis and the effects of antiangiogenesis therapy on the coagulation system and risk of thrombosis.

Keywords

Vascular Endothelial Growth Factor Tissue Factor Coagulation System Tissue Factor Pathway Inhibitor Tissue Factor Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Khorana AA. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost. 1:2463–2465, 2003.PubMedCrossRefGoogle Scholar
  2. 2.
    Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, and ten Cate JW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 327:1128–1133, 1992.PubMedCrossRefGoogle Scholar
  3. 3.
    Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm. 62:S4–6, 2005.PubMedGoogle Scholar
  4. 4.
    Rickles FR, and Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood. 62:14–31, 1983.PubMedGoogle Scholar
  5. 5.
    Sun NC, McAfee WM, Hum GJ, and Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol. 71:10–16, 1979.PubMedGoogle Scholar
  6. 6.
    Sierko E, and Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 30:95–108, 2004.PubMedCrossRefGoogle Scholar
  7. 7.
    Abbasciano V, Bianchi MP, Trevisani L, Sartori S, Gilli G, and Zavagli G. Platelet activation and fibrinolysis in large bowel cancer. Oncology. 52:381–384, 1995.PubMedCrossRefGoogle Scholar
  8. 8.
    Abbasciano V, Tassinari D, Sartori S, Trevisani L, Arcudi D, Bianchi MP, and Liboni A. Usefulness of coagulation markers in staging of gastric cancer. Cancer Detect Prev. 19:331–336, 1995.PubMedGoogle Scholar
  9. 9.
    Ferriere JP, Bernard D, Legros M, Chassagne J, Chollet P, Gaillard G, and Plagne R. beta-Thromboglobulin in patients with breast cancer. Am J Hematol. 19:47–53, 1985.PubMedCrossRefGoogle Scholar
  10. 10.
    Milroy R, Douglas JT, Campbell J, Carter R, Lowe GD, and Banham SW. Abnormal haemostasis in small cell lung cancer. Thorax. 43:978–981, 1988.PubMedCrossRefGoogle Scholar
  11. 11.
    Yazaki T, Inage H, Iizumi T, Koyama A, Kanoh S, Koiso K, Narita M, and Tojo S. Studies on platelet function in patients with prostatic cancer. Preliminary report. Urology. 30:60–63, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    Gasic GJ, Gasic TB, and Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 61:46–52, 1968.Google Scholar
  13. 13.
    Browder T, Folkman J, and Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem. 275:1521–1524, 2000.PubMedCrossRefGoogle Scholar
  14. 14.
    Folkman J, Browder T, and Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost. 86:23–33, 2001.PubMedGoogle Scholar
  15. 15.
    Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, and Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA. 103:855–860, 2006.Google Scholar
  16. 16.
    Pipili-Synetos E, Papadimitriou E, and Maragoudakis ME. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol. 125:1252–1257, 1998.PubMedCrossRefGoogle Scholar
  17. 17.
    Rhee JS, Black M, Schubert U, Fischer S, Morgenstern E, Hammes HP, and Preissner KT. The functional role of blood platelet components in angiogenesis. Thromb Haemost. 92:394–402, 2004.PubMedGoogle Scholar
  18. 18.
    Ben-Ezra J, Sheibani K, Hwang DL, and Lev-Ran A. Megakaryocyte synthesis is the source of epidermal growth factor in human platelets. Am J Pathol. 137:755–759, 1990.PubMedGoogle Scholar
  19. 19.
    Daly ME, Makris A, Reed M, and Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst. 95:1660–1673, 2003.PubMedCrossRefGoogle Scholar
  20. 20.
    Kaplan DR, Chao FC, Stiles CD, Antoniades HN, and Scher CD. Platelet alpha granules contain a growth factor for fibroblasts. Blood. 53:1043–1052, 1979.PubMedGoogle Scholar
  21. 21.
    Mohle R, Green D, Moore MA, Nachman RL, and Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA. 94:663–668, 1997.Google Scholar
  22. 22.
    Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 80:171–175, 1998.PubMedGoogle Scholar
  23. 23.
    Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, and Selby PJ. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 77:956–964, 1998.PubMedCrossRefGoogle Scholar
  24. 24.
    Iruela-Arispe ML, Bornstein P, and Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A. 88:5026–5030, 1991.Google Scholar
  25. 25.
    Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, and Sharpe RJ. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 247:77–79, 1990.PubMedCrossRefGoogle Scholar
  26. 26.
    Italiano JE, Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, and Klement GL. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 111:1227–1233, 2008.PubMedCrossRefGoogle Scholar
  27. 27.
    Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, and Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 96:4216–4221, 2000.PubMedGoogle Scholar
  28. 28.
    Brill A, Dashevsky O, Rivo J, Gozal Y, and Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res. 67:30–38, 2005.PubMedCrossRefGoogle Scholar
  29. 29.
    Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 24:1015–1022, 2004.PubMedCrossRefGoogle Scholar
  30. 30.
    Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost. 86:66–74, 2001.PubMedGoogle Scholar
  31. 31.
    Walker CP, and Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth. 88:848–863, 2002.PubMedCrossRefGoogle Scholar
  32. 32.
    Bajaj MS, Birktoft JJ, Steer SA, and Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 86:959–972, 2001.PubMedGoogle Scholar
  33. 33.
    Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, and Hall CL. Tissue factor pathway inhibitor binds to platelet thrombospondin-1. J Biol Chem. 275:31715–31721, 2000.PubMedCrossRefGoogle Scholar
  34. 34.
    Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, et al. Role of tissue factor in embryonic blood vessel development. Nature. 383:73–75, 1996.PubMedCrossRefGoogle Scholar
  35. 35.
    Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:435–439, 1996.PubMedCrossRefGoogle Scholar
  36. 36.
    Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol. 152:399–411, 1998.PubMedGoogle Scholar
  37. 37.
    Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, and Nawroth PP. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 94:1320–1327, 1994.PubMedCrossRefGoogle Scholar
  38. 38.
    Blum S, Issbruker K, Willuweit A, Hehlgans S, Lucerna M, Mechtcheriakova D, Walsh K, von der Ahe D, Hofer E, and Clauss M. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem. 276:33428–33434, 2001.PubMedCrossRefGoogle Scholar
  39. 39.
    Contrino J, Hair G, Kreutzer DL, and Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 2:209–215, 1996.PubMedCrossRefGoogle Scholar
  40. 40.
    Hair GA, Padula S, Zeff R, Schmeizl M, Contrino J, Kreutzer DL, de Moerloose P, Boyd AW, Stanley I, Burgess AW, et al. Tissue factor expression in human leukemic cells. Leuk Res. 20:1–11, 1996.PubMedCrossRefGoogle Scholar
  41. 41.
    Guan M, Jin J, Su B, Liu WW, and Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem. 35:321–325, 2002.PubMedCrossRefGoogle Scholar
  42. 42.
    Sawada M, Miyake S, Ohdama S, Matsubara O, Masuda S, Yakumaru K, and Yoshizawa Y. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer. 79:472–477, 1999.PubMedCrossRefGoogle Scholar
  43. 43.
    Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, Nakamura S, and Shiku H. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol. 69:247–254, 2002.PubMedCrossRefGoogle Scholar
  44. 44.
    Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, and Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost. 80:894–898, 1998.PubMedGoogle Scholar
  45. 45.
    Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, and Imamura M. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer. 88:295–301, 2000.PubMedCrossRefGoogle Scholar
  46. 46.
    Koomagi R, and Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer. 79:19–22, 1998.PubMedCrossRefGoogle Scholar
  47. 47.
    Goldsack NR, Chambers RC, Dabbagh K, and Laurent GJ. Thrombin. Int J Biochem Cell Biol. 30:641–646, 1998.PubMedCrossRefGoogle Scholar
  48. 48.
    Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 407:258–264, 2000.PubMedCrossRefGoogle Scholar
  49. 49.
    Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, and Voelkel NF. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol. 275:H1054–1061, 1998.PubMedGoogle Scholar
  50. 50.
    Fernandez PM, Patierno SR, and Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost. 30:31–44, 2004.PubMedGoogle Scholar
  51. 51.
    Degen JL, Drew AF, Palumbo JS, Kombrinck KW, Bezerra JA, Danton MJ, Holmback K, and Suh TT. Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann N Y Acad Sci. 936:276–290, 2001.PubMedCrossRefGoogle Scholar
  52. 52.
    Henschen A, Lottspeich F, Kehl M, and Southan C. Covalent structure of fibrinogen. Ann N Y Acad Sci. 408:28–43, 1983.PubMedCrossRefGoogle Scholar
  53. 53.
    Buller HR, van Doormaal FF, van Sluis GL, and Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 5 Suppl 1:246–254, 2007.CrossRefGoogle Scholar
  54. 54.
    Palumbo JS, and Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 120 Suppl 2:S22–28, 2007.CrossRefGoogle Scholar
  55. 55.
    Rickles FR, Patierno S, and Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 124:58S–68S, 2003.PubMedCrossRefGoogle Scholar
  56. 56.
    Lalla RV, Goralnick SJ, Tanzer ML, and Kreutzer DL. Fibrin induces IL-8 expression from human oral squamous cell carcinoma cells. Oral Oncol. 37:234–242, 2001.PubMedCrossRefGoogle Scholar
  57. 57.
    Khorana AA, and Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 5:655–663, 2004.PubMedCrossRefGoogle Scholar
  58. 58.
    Wang H, Doll JA, Jiang K, Cundiff DL, Czarnecki JS, Wilson M, Ridge KM, and Soff GA. Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis. Cancer Res. 66:7211–7215, 2006.PubMedCrossRefGoogle Scholar
  59. 59.
    Wang H, Schultz R, Hong J, Cundiff DL, Jiang K, and Soff GA. Cell surface-dependent generation of angiostatin4.5. Cancer Res. 64:162–168, 2004.PubMedCrossRefGoogle Scholar
  60. 60.
    Sharma MC, and Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des. 13:3568–3575, 2007.PubMedCrossRefGoogle Scholar
  61. 61.
    Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A. 94:10868–10872, 1997.Google Scholar
  62. 62.
    Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56:4887–4890, 1996.PubMedGoogle Scholar
  63. 63.
    Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev. 19:97–107, 2000.PubMedCrossRefGoogle Scholar
  64. 64.
    Hanford HA, Wong CA, Kassan H, Cundiff DL, Chandel N, Underwood S, Mitchell CA, and Soff GA. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res. 63:4275–4280, 2003.PubMedGoogle Scholar
  65. 65.
    Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood. 92:4730–4741, 1998.PubMedGoogle Scholar
  66. 66.
    Lannutti BJ, Gately ST, Quevedo ME, Soff GA, and Paller AS. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res. 57:5277–5280, 1997.PubMedGoogle Scholar
  67. 67.
    Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 394:287–291, 1998.PubMedCrossRefGoogle Scholar
  68. 68.
    Soff GA, Wang H, Cundiff DL, Jiang K, Martone B, Rademaker AW, Doll JA, and Kuzel TM. In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin Cancer Res. 11:6218–6225, 2005.PubMedCrossRefGoogle Scholar
  69. 69.
    Levine MN, Lee AY, and Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost. 1:1456–1463, 2003.PubMedCrossRefGoogle Scholar
  70. 70.
    McCulloch P, and George WD. Warfarin inhibition of metastasis: the role of anticoagulation. Br J Surg. 74:879–883, 1987.PubMedCrossRefGoogle Scholar
  71. 71.
    Neubauer BL, Bemis KG, Best KL, Goode RL, Hoover DM, Smith GF, Tanzer LR, and Merriman RL. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat. J Urol. 135:163–166, 1986.PubMedGoogle Scholar
  72. 72.
    Colucci M, Delaini F, de Bellis Vitti G, Locati D, Poggi A, Semeraro N, and Donati MB. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol. 32:1689–1691, 1983.PubMedCrossRefGoogle Scholar
  73. 73.
    Brown DC, Purushotham AD, and George WD. Inhibition of pulmonary tumor seeding by antiplatelet and fibrinolytic therapy in an animal experimental model. J Surg Oncol. 55:154–159, 1994.PubMedCrossRefGoogle Scholar
  74. 74.
    Nierodzik ML, and Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 10:355–362, 2006.PubMedCrossRefGoogle Scholar
  75. 75.
    Karpatkin S. Role of thrombin in tumor angiogenesis, implantation, and metastasis. Pathophysiol Haemost Thromb. 33 Suppl 1:54–55, 2003.CrossRefGoogle Scholar
  76. 76.
    Caunt M, Huang YQ, Brooks PC, and Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost. 1:2097–2102, 2003.PubMedCrossRefGoogle Scholar
  77. 77.
    Bobek V, and Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother. 58:213–219, 2004.PubMedCrossRefGoogle Scholar
  78. 78.
    Lundbeck F, Mogensen P, and Jeppesen N. Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin and urokinase. J Urol. 130:1087–1089, 1983.PubMedGoogle Scholar
  79. 79.
    Khan O, Hensby CN, and Williams G. Prostacyclin in prostatic cancer: a better marker than bone scan or serum acid phosphatase? Br J Urol. 54:26–31, 1982.PubMedCrossRefGoogle Scholar
  80. 80.
    Daly L. The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Metastasis. 9:3–11, 1991.PubMedCrossRefGoogle Scholar
  81. 81.
    Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, and Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost. 82:947–952, 1999.PubMedGoogle Scholar
  82. 82.
    von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, and Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 16:815–824, 2000.Google Scholar
  83. 83.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349:146–153, 2003.PubMedCrossRefGoogle Scholar
  84. 84.
    Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, and Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 22:1944–1948, 2004.PubMedCrossRefGoogle Scholar
  85. 85.
    Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 23:2130–2135, 2005.PubMedCrossRefGoogle Scholar
  86. 86.
    Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, and Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2:1266–1271, 2004.PubMedCrossRefGoogle Scholar
  87. 87.
    El Accaoui RN, Shamseddeen WA, and Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost. 97:1031–1036, 2007.PubMedGoogle Scholar
  88. 88.
    Goz M, Eren MN, and Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis. 25:224–226, 2008.PubMedCrossRefGoogle Scholar
  89. 89.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342, 2004.PubMedCrossRefGoogle Scholar
  90. 90.
    Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, and Benson AB III. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 25:1539–1544, 2007.Google Scholar
  91. 91.
    Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, and Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 23:3697–3705, 2005.PubMedCrossRefGoogle Scholar
  92. 92.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, and Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 21:60–65, 2003.PubMedCrossRefGoogle Scholar
  93. 93.
    Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 23:792–799, 2005.PubMedCrossRefGoogle Scholar
  94. 94.
    Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III, Gaudreault J, Damico LA, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 22:2184–2191, 2004.Google Scholar
  95. 95.
    Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 99:1232–1239, 2007.PubMedCrossRefGoogle Scholar
  96. 96.
    Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, and Hoekman K. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 22:1500–1505, 2002.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Memorial Sloan-Kettering Cancer CenterHoward-802, New YorkUSA

Personalised recommendations